Mithra Signs LSA for Commercialization of Myring™ in Germany, the biggest market in Europe

/in , /by

Mithra grants exclusive license to Hormosan for commercialization of vaginal contraceptive ring in Germany Germany is the largest European market in terms of volumes, with 3 million vaginal rings sold per year Agreement follows licensing deals for Myring™ with market leaders in the U.S., Europe, Russia, Australia, Middle East, Latin and South America Liege, Belgium, […]

Read more →

Tibelia®, First Tibolone-Based Hormone Therapy Approved in Canada

/in , /by

The Canadian Health authorities have granted the Marketing Authorization for Tibelia®, the company’s tibolone-based product for use in Hormone Therapy (HT). First tibolone-based hormone treatment to be available in Canada, offering a true new option for women with a proven efficacy, tolerability and safety profile The introduction of Tibelia® in Canada plays a crucial role […]

Read more →

Information on the Total Number of Voting Rights (Denominator)

/in , /by

Liege, Belgium, 29 April 2019 – 17:45 CEST – In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Mithra Pharmaceuticals SA announces the following information, following the issuance of 24,750 new shares on 24 April 2019 for an amount of EUR 84,690 as the result of the […]

Read more →

Mithra Signs License and Supply Agreement for Commercialization of Myring™ in Latin and South America

/in , /by

Mithra grants exclusive 10-year license to Megalabs for commercialization of vaginal contraceptive ring in Argentina, Paraguay and the Dominican Republic Product to be manufactured at Mithra CDMO facility in Belgium Agreement follows licensing deals for Myring™ with international market leaders in the U.S., Europe, Russia, Australia, Middle East and Chile Liege, Belgium, 25 April 2019 […]

Read more →

Mithra announces new agreement with GSP for development of an additional injectable

/in , /by

Agreement with Generic Specialty Pharma (GSP), a leading generics player, for development and supply of a fifth hormonal injectable. Expansion of Mithra CDMO’s portfolio of activities, confirming its profile as a unique industrial partner in the development and production of a complete range of specialized medical products and devices. Liege, Belgium, 18 April 2019 – […]

Read more →

Mithra Releases 2018 Annual Report and Invitation to its General Shareholders’ Meeting

/in /by

Liege, Belgium, 8 April 2019 – 7:30  CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces the publication of its 2018 Annual Report and the invitation to its Ordinary and Extraordinary General Shareholders’ meeting. Annual Report The Annual Report which outlines Mithra’s achievements in 2018 includes the following information: Overview of […]

Read more →

Mithra wins essenscia Innovation Award 2019 for its new generation contraceptive pill, Estelle®

/in , /by

Mithra wins the Essenscia Innovation Award, the most prestigious prize for industrial innovation in Belgium Jury of experts recognize the major breakthrough and worldwide potential of this new generation contraceptive pill Capping more than 20 years of research and development, this award was presented by her Royal Highness, the Princess Astrid, during a ceremony at […]

Read more →

Mithra receives Orphan Drug Designation from FDA for E4 in neonatal encephalopathy treatment

/in , /by

The US Food and Drug Administration granted E4 an ODD for the treatment of life-threatening hypoxic ischemic encephalopathy (HIE) This new designation expands E4’s broad potential in therapeutic areas beyond the leading indications in women’s health Mithra continues its preclinical studies in HIE, a severe pediatric syndrome that affects 30,000 newborns each year in Europe […]

Read more →

Mithra Demonstrates Further Estetrol’s Unique Profile at the Annual Meeting of the Endocrine Society

/in , /by

Liege, Belgium, 25 March 2019 – 7 :30  CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health has presented the results of a new study on Estetrol (E4) at the 101st Annual Meeting of the Endocrine Society (ENDO 2019) held from March 23 to 26 in New Orleans (U.S.)  

Read more →

Mithra Signs License and Supply Agreement for Commercialization of Tibelia® in Chile

/in , /by

Mithra strengthens its presence in the fast-growing Chilean market with an agreement for commercialization of the hormone treatment Tibelia® with Saval Pharmaceuticals Tibelia® is currently marketed in about ten countries through existing license and supply agreements and just adds an additional market in Spain after winning a public tender Liege, Belgium, 05 March 2019 – […]

Read more →